McClelland and colleagues have summarized numerous inhibitors developed to target IL-8 or its receptor CXCR1/2 for the treatment of chronic obstructive pulmonary disease (COPD), asthma, diabetes, pneumonia, and solid tumors, including prostate cancer [62]. This evidence concerns the gene CXCL8 and prostate cancer.